Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week Open-Label Extension Study to Evaluate TNX-102 SL Taken Daily at Bedtime in Patients With PTSD

NCT03110575 is registered in ClinicalTrials.gov with Tonix Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03110575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03110575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week Open-Label Extension Study to Evaluate TNX-102 SL Taken Daily at Bedtime in Patients With PTSD
Lead sponsor
Tonix Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 20, 2017
Completion date
July 27, 2018
Enrollment
190 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

ptsd